At a glance
ClinicalIndex Comparison Record- ✓ECOG performance status 0 or 1
- ✓Histologically confirmed recurrent or metastatic adenoid cystic carcinoma not amenable to curative surgery or radiotherapy
- ✓Measurable disease per RECIST 1.1
- ✓Evidence of disease progression within 6 months of enrollment or worsening disease-related symptoms
- ✕Prior treatment with immune checkpoint inhibitors (anti-PD-1/PD-L1)
- ✕Prior treatment with VEGF or VEGFR inhibitors
- ✕Active autoimmune disease that might deteriorate with immunotherapy (except type I diabetes, vitiligo, psoriasis, thyroid disease not requiring immunosuppression)
- ✕Prior organ transplantation including allogeneic stem-cell transplantation
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma (ACC)
In Brief
A Phase 2 clinical trial evaluating Avelumab and Axitinib for Metastatic Adenoid Cystic Carcinoma and 2 related conditions. Completed, enrolled 40 participants across 1 site.
Detailed Summary
This phase II trial studies how well axitinib and avelumab work in treating patients with adenoid cystic carcinoma that has come back or spread to other places in the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving axitinib and avelumab together may help to control adenoid cystic carcinoma.
Study Details
Timeline
Interventions
Given IV
Given PO